Biomaterial-Facilitated Immunotherapy for Established Oral Cancers

David G. Leach; Neeraja Dharmaraj; Tania L. Lopez-Silva; Jose Rodriguez Venzor; Brett H. Pogostin; Andrew G. Sikora; Jeffrey D. Hartgerink; Simon Young

doi:10.1021/acsbiomaterials.0c01575

Biomaterial-Facilitated Immunotherapy for Established Oral Cancers

David G. Leach, Neeraja Dharmaraj, Tania L. Lopez-Silva, Jose Rodriguez Venzor, Brett H. Pogostin, Andrew G. Sikora, Jeffrey D. Hartgerink, Simon Young

Head & Neck Surgery

Research output: Contribution to journal › Article › peer-review

24 Scopus citations

Abstract

We evaluated a peptide-based immunotherapy termed SynerGel: an injectable, biomaterial-based platform for intratumoral drug delivery. A drug-mimicking peptide hydrogel named L-NIL-MDP was loaded with an antitumor cyclic dinucleotide (CDN) immunotherapy agonist. The biomaterial combines inducible nitric oxide synthase (iNOS) inhibition with controlled delivery of CDNs, demonstrating between 4- and 20-fold slower drug release than commercially available hydrogels. SynerGel allowed for immune-mediated elimination of established treatment-resistant oral tumors in a murine model, with a median survival of 67.5 days compared with 44 days in no-treatment control. This report details findings for a promising therapy showing improved efficacy over previous hydrogel systems.

Original language	English (US)
Pages (from-to)	415-421
Number of pages	7
Journal	ACS Biomaterials Science and Engineering
Volume	7
Issue number	2
DOIs	https://doi.org/10.1021/acsbiomaterials.0c01575
State	Published - Feb 8 2021

Keywords

bioactive peptide biomaterial
controlled drug release
immunotherapy
intratumoral hydrogel

ASJC Scopus subject areas

Biomaterials
Biomedical Engineering

Access to Document

10.1021/acsbiomaterials.0c01575

Cite this

@article{6deb79ab0f0f4bf980b162b7b8422312,

title = "Biomaterial-Facilitated Immunotherapy for Established Oral Cancers",

abstract = "We evaluated a peptide-based immunotherapy termed SynerGel: an injectable, biomaterial-based platform for intratumoral drug delivery. A drug-mimicking peptide hydrogel named L-NIL-MDP was loaded with an antitumor cyclic dinucleotide (CDN) immunotherapy agonist. The biomaterial combines inducible nitric oxide synthase (iNOS) inhibition with controlled delivery of CDNs, demonstrating between 4- and 20-fold slower drug release than commercially available hydrogels. SynerGel allowed for immune-mediated elimination of established treatment-resistant oral tumors in a murine model, with a median survival of 67.5 days compared with 44 days in no-treatment control. This report details findings for a promising therapy showing improved efficacy over previous hydrogel systems.",

keywords = "bioactive peptide biomaterial, controlled drug release, immunotherapy, intratumoral hydrogel",

author = "Leach, {David G.} and Neeraja Dharmaraj and Lopez-Silva, {Tania L.} and Venzor, {Jose Rodriguez} and Pogostin, {Brett H.} and Sikora, {Andrew G.} and Hartgerink, {Jeffrey D.} and Simon Young",

note = "Publisher Copyright: {\textcopyright} 2021 American Chemical Society.",

year = "2021",

month = feb,

day = "8",

doi = "10.1021/acsbiomaterials.0c01575",

language = "English (US)",

volume = "7",

pages = "415--421",

journal = "ACS Biomaterials Science and Engineering",

issn = "2373-9878",

publisher = "American Chemical Society",

number = "2",

}

TY - JOUR

T1 - Biomaterial-Facilitated Immunotherapy for Established Oral Cancers

AU - Leach, David G.

AU - Dharmaraj, Neeraja

AU - Lopez-Silva, Tania L.

AU - Venzor, Jose Rodriguez

AU - Pogostin, Brett H.

AU - Sikora, Andrew G.

AU - Hartgerink, Jeffrey D.

AU - Young, Simon

PY - 2021/2/8

Y1 - 2021/2/8

N2 - We evaluated a peptide-based immunotherapy termed SynerGel: an injectable, biomaterial-based platform for intratumoral drug delivery. A drug-mimicking peptide hydrogel named L-NIL-MDP was loaded with an antitumor cyclic dinucleotide (CDN) immunotherapy agonist. The biomaterial combines inducible nitric oxide synthase (iNOS) inhibition with controlled delivery of CDNs, demonstrating between 4- and 20-fold slower drug release than commercially available hydrogels. SynerGel allowed for immune-mediated elimination of established treatment-resistant oral tumors in a murine model, with a median survival of 67.5 days compared with 44 days in no-treatment control. This report details findings for a promising therapy showing improved efficacy over previous hydrogel systems.

AB - We evaluated a peptide-based immunotherapy termed SynerGel: an injectable, biomaterial-based platform for intratumoral drug delivery. A drug-mimicking peptide hydrogel named L-NIL-MDP was loaded with an antitumor cyclic dinucleotide (CDN) immunotherapy agonist. The biomaterial combines inducible nitric oxide synthase (iNOS) inhibition with controlled delivery of CDNs, demonstrating between 4- and 20-fold slower drug release than commercially available hydrogels. SynerGel allowed for immune-mediated elimination of established treatment-resistant oral tumors in a murine model, with a median survival of 67.5 days compared with 44 days in no-treatment control. This report details findings for a promising therapy showing improved efficacy over previous hydrogel systems.

KW - bioactive peptide biomaterial

KW - controlled drug release

KW - immunotherapy

KW - intratumoral hydrogel

UR - http://www.scopus.com/inward/record.url?scp=85100242708&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85100242708&partnerID=8YFLogxK

U2 - 10.1021/acsbiomaterials.0c01575

DO - 10.1021/acsbiomaterials.0c01575

M3 - Article

C2 - 33470801

AN - SCOPUS:85100242708

SN - 2373-9878

VL - 7

SP - 415

EP - 421

JO - ACS Biomaterials Science and Engineering

JF - ACS Biomaterials Science and Engineering

IS - 2

ER -

Biomaterial-Facilitated Immunotherapy for Established Oral Cancers

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this